Magpie Trial Co-ordinating Centre, Institute of Health Sciences, Old Road, Headington, Oxford OX3 7LF, UK.
BMC Pregnancy Childbirth. 2004 Mar 8;4(1):5. doi: 10.1186/1471-2393-4-5.
The Magpie Trial compared magnesium sulphate with placebo for women with pre-eclampsia. 10,141 women were recruited, 8804 before delivery. Overall, 9024 children were included in the analysis of outcome at discharge from hospital. Magnesium sulphate more than halved the risk of eclampsia, and probably reduced the risk of maternal death. There did not appear to be any substantive harmful effects on the baby, in the short term. It is now important to assess whether these benefits persist, and to provide adequate reassurance about longer term safety.The main objective of the Magpie Trial Follow Up Study is to assess whether in utero exposure to magnesium sulphate has a clinically important effect on the child's chance of surviving without major neurosensory disability. Other objectives are to assess long term outcome for the mother, and to develop and assess appropriate strategies for following up large numbers of children in perinatal trials. STUDY DESIGN: Follow up is only feasible in selected centres. We therefore anticipate contacting 2800-3350 families, for 2435-2915 of whom the woman was randomised before delivery. A further 280-335 children would have been eligible for follow up if they had survived. The total sample size for the children is therefore 3080-3685, 2680-3210 of whom will have been born to women randomised before delivery.Families eligible for the follow up will be contacted, and surviving children screened using the Ages and Stages Questionnaires. Children who screen positive, and a sample of those who screen negative, will whenever possible have a paediatric and neurodevelopmental assessment. When women are contacted to ask how their child is, they will also be asked about their own health. The primary outcome is a composite measure of death or neurosensory disability for the child at 18 months. DISCUSSION: The Follow Up Study began in 2002, and now involves collaborators in 19 countries. Data collection will close at the end of 2003.
喜鹊试验比较了硫酸镁与安慰剂对先兆子痫妇女的疗效。共招募了10141名妇女,其中8804名在分娩前参与试验。总体而言,9024名儿童纳入了出院时的结局分析。硫酸镁使子痫风险降低了一半以上,且可能降低了孕产妇死亡风险。短期内,对婴儿似乎没有任何实质性的有害影响。现在重要的是评估这些益处是否持续存在,并提供关于长期安全性的充分保证。喜鹊试验随访研究的主要目的是评估子宫内接触硫酸镁对儿童无重大神经感觉残疾存活几率是否有临床重要影响。其他目的是评估母亲的长期结局,以及制定和评估围产期试验中对大量儿童进行随访的适当策略。
随访仅在选定的中心可行。因此,我们预计联系2800 - 3350个家庭,其中2435 - 2915名妇女在分娩前被随机分组。如果另外280 - 335名儿童存活下来,他们也有资格接受随访。因此,儿童的总样本量为3080 - 3685名,其中2680 - 3210名儿童的母亲在分娩前被随机分组。符合随访条件的家庭将被联系,存活儿童将使用《年龄与发育阶段问卷》进行筛查。筛查呈阳性的儿童以及一部分筛查呈阴性的儿童,将尽可能接受儿科和神经发育评估。当联系妇女询问其孩子的情况时,也会询问她们自身的健康状况。主要结局是儿童在18个月时死亡或神经感觉残疾的综合指标。
随访研究于2002年开始,目前有19个国家的合作者参与。数据收集将于2003年底结束。